- Home
- ITOS vs KIO Comparison
ITOS vs KIO Comparison
Compare ITOS & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- KIO
- Stock Information
- Founded
- ITOS 2011
- KIO 2011
- Country
- ITOS United States
- KIO United States
- Employees
- ITOS N/A
- KIO 2400
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- KIO Investment Managers
- Sector
- ITOS Health Care
- KIO Finance
- Exchange
- ITOS Nasdaq
- KIO Nasdaq
- Market Cap
- ITOS 450.9M
- KIO 522.7M
- IPO Year
- ITOS 2020
- KIO N/A
- Fundamental
- Price
- ITOS N/A
- KIO $12.58
- Analyst Decision
- ITOS Hold
- KIO
- Analyst Count
- ITOS 6
- KIO 0
- Target Price
- ITOS $10.40
- KIO N/A
- AVG Volume (30 Days)
- ITOS 1.6M
- KIO 136.5K
- Earning Date
- ITOS 08-06-2025
- KIO 01-01-0001
- Dividend Yield
- ITOS N/A
- KIO 10.82%
- EPS Growth
- ITOS N/A
- KIO N/A
- EPS
- ITOS N/A
- KIO N/A
- Revenue
- ITOS N/A
- KIO N/A
- Revenue This Year
- ITOS N/A
- KIO N/A
- Revenue Next Year
- ITOS N/A
- KIO N/A
- P/E Ratio
- ITOS N/A
- KIO N/A
- Revenue Growth
- ITOS 177.89
- KIO N/A
- 52 Week Low
- ITOS $4.80
- KIO $10.52
- 52 Week High
- ITOS $17.63
- KIO $13.59
- Technical
- Relative Strength Index (RSI)
- ITOS 1.63
- KIO 54.64
- Support Level
- ITOS $10.10
- KIO $12.38
- Resistance Level
- ITOS $10.17
- KIO $12.54
- Average True Range (ATR)
- ITOS 0.03
- KIO 0.10
- MACD
- ITOS -1.20
- KIO 0.01
- Stochastic Oscillator
- ITOS 0.00
- KIO 97.09
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.